Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
Preparatory Infrastructure Work for Pilot Plant and Mining on the HMS TitanBeach Titanium Project in Morocco Begins. Company Options Issued
